Lilly Scraps Oncology Candidate - Analyst Blog - NASDAQ.com NASDAQ ... the phase III PRELUDE study showed that enzastaurin failed to show a statistically significant improvement in disease-free survival compared to placebo in patients at high risk of relapse following treatment with Roche's ( RHHBY ) Rituxan ... |
